December 17, 2008 - Bioheart Inc. announced yesterday its plan to shift focus from several non-core technology platforms to concentrate on the treatment of patients suffering from heart failure.
Bioheart will spin out or sell off its interest in several non-core technology platforms to which it holds the rights to multiple patents and patents pending related to these non-core technologies as well as proprietary know-how and trade secrets. Animal data supporting the proof of concept for some of these technologies is also available from the company.
The technologies planned for spin out or sell off include:
Biopace -- A biological pacemaker
MyoValve -- A cell seeding method for repairing and building biological heart valves.
EndoCell -- A system for bedside preparation of adipose tissue for delivery of endothelial progenitor cells to the adventitia of coronary arteries for prevention of restenosis following balloon angioplasty, stenting or atherectomy.
AortaCell -- Cell compositions and delivery systems for repairing aortic aneurysms or for reinforcing the neck area in aortas repaired with an endovascular stent graft.
In addition, Bioheart is seeking a strategic partner for the development of its bi-ventricular pacemaker technology, called MyoStim,which utilizes a patented electrical stimulation software program and an additional pacemaker lead to enhance cell transplantation.
Bioheart says it is strategically focused on commercializing patented technologies for reducing and repairing heart muscle damage caused by heart attacks. It markets advanced heart failure monitoring devices including the Bioheart 3370 Heart Failure Monitor and the Bioheart-Monebo CardioBelt ECG Acquisition Device.
For more information: www.bioheartinc.com.